These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 33640709)
1. Factors affecting response to 5-azacytidine and prognosis of myelodysplastic syndrome. Is long-term survival a realistic goal? Diamantopoulos PT; Viniou NA Leuk Res; 2021 Apr; 103():106543. PubMed ID: 33640709 [TBL] [Abstract][Full Text] [Related]
2. Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry. Diamantopoulos PT; Pappa V; Symeonidis A; Kotsianidis I; Galanopoulos A; Papadaki H; Anagnostopoulos A; Vassilopoulos G; Zikos P; Hatzimichael E; Papaioannou M; Megalakaki A; Kotsopoulou M; Repousis P; Dimou M; Solomou E; Pontikoglou C; Kyriakakis G; Tsokanas D; Papoutselis MK; Papageorgiou S; Kourakli A; Panayiotidis P; Viniou NA Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):114-121. PubMed ID: 31884152 [TBL] [Abstract][Full Text] [Related]
3. Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study. Lee JH; Kim YJ; Sohn SK; Yoon SS; Kim H; Cheong JW; Lee WS; Lee GW; Lim SN; Kim MK; Lee HS; Kim HJ; Leuk Res; 2017 Sep; 60():135-144. PubMed ID: 28826063 [TBL] [Abstract][Full Text] [Related]
4. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts. Baek DW; Lee YJ; Kim H; Ahn SY; Ahn JS; Shin HJ; Lee WS; Lee SM; Song IC; Lee HS; Park SW; Choi Y; Cho YY; Bae SH; Kim HJ; Sohn SK; Moon JH Ann Hematol; 2018 Dec; 97(12):2309-2317. PubMed ID: 30073392 [TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. Jung KS; Kim YJ; Kim YK; Park SK; Kim HG; Kim SJ; Park J; Choi CW; Do YR; Kim I; Park S; Mun YC; Jeong SH; Kim MK; Yi HG; Chang MH; Kim SY; Lee JH; Jang JH Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):656-664. PubMed ID: 31375393 [TBL] [Abstract][Full Text] [Related]
6. Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine. Li X; Chang C; He Q; Xu F; Zhang Q; Wu L; Su J; Zhang X; Zhou L; Wu D; Song L; Zhang Z Leuk Res; 2013 Nov; 37(11):1516-21. PubMed ID: 24084368 [TBL] [Abstract][Full Text] [Related]
7. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405 [TBL] [Abstract][Full Text] [Related]
8. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Jabbour E; Short NJ; Montalban-Bravo G; Huang X; Bueso-Ramos C; Qiao W; Yang H; Zhao C; Kadia T; Borthakur G; Pemmaraju N; Sasaki K; Estrov Z; Cortes J; Ravandi F; Alvarado Y; Komrokji R; Sekeres MA; Steensma DP; DeZern A; Roboz G; Kantarjian H; Garcia-Manero G Blood; 2017 Sep; 130(13):1514-1522. PubMed ID: 28774880 [TBL] [Abstract][Full Text] [Related]
9. Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes. Lee YJ; Park SW; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Lee WS; Lee SM; Joo YD; Kim H; Lee HS; Kim YS; Cho YY; Moon JH; Sohn SK Ann Hematol; 2016 Oct; 95(11):1795-804. PubMed ID: 27530461 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. Zeidan AM; Lee JW; Prebet T; Greenberg P; Sun Z; Juckett M; Smith MR; Paietta E; Gabrilove J; Erba HP; Tallman MS; Gore SD; Br J Haematol; 2014 Aug; 166(3):352-9. PubMed ID: 24712482 [TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry. Diamantopoulos P; Koumbi D; Kotsianidis I; Pappa V; Symeonidis A; Galanopoulos A; Zikos P; Papadaki HA; Panayiotidis P; Dimou M; Hatzimichael E; Vassilopoulos G; Delimpasis S; Mparmparousi D; Papageorgiou S; Variami E; Kyrtsonis MC; Megalakaki A; Kotsopoulou M; Repousis P; Adamopoulos I; Kontopidou F; Christoulas D; Kourakli A; Tsokanas D; Konstantinos Papoutselis M; Kyriakakis G; Viniou NA; Cancer Med; 2019 May; 8(5):2056-2063. PubMed ID: 30897290 [TBL] [Abstract][Full Text] [Related]
12. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants. Xie M; Jiang Q; Xie Y Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977 [TBL] [Abstract][Full Text] [Related]
13. Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes. Papadopoulos V; Diamantopoulos PT; Papageorgiou SG; Papoutselis M; Vrachiolias G; Pappa V; Galanopoulos AG; Vassilakopoulos TP; Hatzimichael E; Zikos P; Papadaki HA; Bouchla A; Panayiotidis P; Megalakaki A; Papaioannou M; Liapis K; Dryllis G; Tsokanas D; Kourakli A; Symeonidis A; Viniou NA; Kotsianidis I Hematol Oncol; 2020 Oct; 38(4):541-553. PubMed ID: 32495951 [TBL] [Abstract][Full Text] [Related]
14. High-dose regimens of hypomethylating agents promote transfusion independence in IPSS lower-risk myelodysplastic syndromes: a meta-analysis of prospective studies. Wan Z; Han B Aging (Albany NY); 2021 Mar; 13(8):11120-11134. PubMed ID: 33818418 [TBL] [Abstract][Full Text] [Related]
15. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update. Joeckel TE; Lübbert M Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063 [TBL] [Abstract][Full Text] [Related]
16. A case report of a very late response to 5-azacytidine in a patient with lower risk myelodysplastic syndrome: Time to update treatment guidelines for lower risk patients. Spetsieris N; Diamantopoulos P; Zervakis K; Giannakopoulou N; Rougala N; Garefalakis G; Skarlatou V; Viniou NA Medicine (Baltimore); 2018 Apr; 97(17):e0505. PubMed ID: 29703015 [TBL] [Abstract][Full Text] [Related]
17. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320 [TBL] [Abstract][Full Text] [Related]
18. Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome. Modi D; Kim S; Singh V; Ayash L; Alavi A; Ratanatharathorn V; Uberti JP; Deol A Leuk Lymphoma; 2019 Nov; 60(11):2762-2770. PubMed ID: 31010370 [TBL] [Abstract][Full Text] [Related]
19. Hypomethylating agents for patients with myelodysplastic syndromes prior to hematopoietic stem cell transplantation: a systematic review and meta-analysis. Qin Y; Kuang P; Zeng Q; Wu Y; Liu T Ann Hematol; 2019 Nov; 98(11):2523-2531. PubMed ID: 31637485 [TBL] [Abstract][Full Text] [Related]
20. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium. Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]